HIV Nucleic Acid Composition With Ag85B for Post-Infection Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Despite significant efforts, there is no effective cure for HIV infection, and existing vaccines have shown limited efficacy, with the RV144 clinical trial achieving only a 31% reduction in HIV infection.
Innovation Solution
A nucleic acid construct containing a nucleic acid sequence encoding an antigen protein from the genus Lentivirus and Ag85B protein is administered to treat and eliminate HIV infection, utilizing an attenuated nef-deleted virus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiretroviral therapy is administered to reduce HIV-associated morbidity and mortality, then the survival rate is improved, but the virus cannot be cured
Solution Approach 1:
The patent combines antiretroviral therapy with a nucleic acid construct encoding HIV antigen and Ag85B protein to create a dual-action treatment. This merging of conventional therapy with immunogenic stimulation aims to both suppress viral replication and induce immune-mediated viral clearance, potentially achieving cure while maintaining survival benefits
Solution Approach 2:
The nucleic acid construct acts as an intermediary that bridges antiretroviral therapy and the host immune system. By encoding HIV antigen and Ag85B protein, it mediates the activation of specific immune responses (CD4+ and CD8+ T cells) that can target and eliminate infected cells, thereby enabling viral cure without compromising the survival benefits of antiretroviral therapy
2Object-affected harmful factors
If HIV vaccines are developed to prevent HIV infection, then the spread of infection can be prevented, but vaccine efficacy has been limited with only 31% effectiveness achieved
Solution Approach 1:
The vaccine composition uses a composite nucleic acid construct containing two distinct antigenic elements: HIV antigen and Ag85B protein from Mycobacterium bovis BCG. This composite approach creates a multi-component immunogen that stimulates broader and more robust immune responses compared to single-antigen vaccines, thereby improving efficacy while still preventing infection spread
Solution Approach 2:
The patent employs nef-deleted attenuated HIV virus as a vector, which represents a parameter change in viral pathogenicity. By deleting the nef gene that contributes to viral immune evasion and pathogenicity, the vaccine maintains immunogenicity while reducing harmful effects, thereby improving the efficacy-to-safety ratio and achieving better protective immunity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nucleic acid construct effectively eliminates HIV from the subject, offering a potential cure by administering it after infection, either alone or in conjunction with antiretroviral drugs.
Implementation Method 1
a nucleic acid construct containing, in an operable manner, a nucleic acid sequence encoding an antigen protein contained in a virus belonging to the genus Lentivirus or a part thereof and a nucleic acid sequence encoding Ag85B protein
Data Source
AI summary
The present disclosure provides a composition for treating a viral infection. In one aspect, the present disclosure provides a composition for treating a viral infection in a subject, the composition containing a nucleic acid construct containing, in an operable manner, a nucleic acid sequence encoding an antigen protein contained in a virus belonging to the genus Lentivirus or a part thereof and a nucleic acid sequence encoding Ag85B protein. In one embodiment, the composition of the present disclosure is administered after the viral infection.